middle.news
Nexalis clears LFO dispute as funding path opens for clinical restart
9:06am on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Nexalis clears LFO dispute as funding path opens for clinical restart
9:06am on Friday 30th of October, 2026 AEDT
Key Points
$371,000 cash balance after $419,000 quarterly operating outflow
LFO facility terminated with no repayment obligation and security released
RDTI forward funding targeted for the December 2026 quarter
Capital raising planned, with timing and structure undecided
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE